A recent study showed that, over the course of 104 weeks treatment, a 7.7% of T2DM patients under dapagliflozin (a commercially available SGLT-2 inhibitor) presented bone fractures, though the exact cause of this increase in fracture risk is rather uncertain (119). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.